Noticias de AKTS_US

Noticias del mercado

Últimas noticias sobre AKTS_US — 115 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AKTS_US ✕ 115 resultados
16/04/2026 AKTS_US — GlobeNewswire
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
16/04/2026 AKTS_US — Investing.com
Aktis Oncology appoints Glenn Gormley to board of directors By Investing.com
15/04/2026 AKTS_US — GuruFocus
Glenn Gormley Net Worth (2026)
12/04/2026 AKTS_US — Insider Monkey
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33
12/04/2026 AKTS_US — Yahoo Finance
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33
12/04/2026 AKTS_US — Insider Monkey
5 Healthcare Stocks Insiders Are Buying
05/04/2026 AKTS_US — Investing.com Nigeria
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer
31/03/2026 AKTS_US — William Blair
William Blair Recognized in "Where You Work Matters" List of Top Employers
31/03/2026 AKTS_US — BioWorld News
Aktis Oncology’s AKY-2519 gains IND approvals
31/03/2026 AKTS_US — TipRanks
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
31/03/2026 AKTS_US — The Manila Times ES ← EN
Aktis Oncology anuncia la autorización de la FDA para las solicitudes de nuevos medicamentos en investigación para AKY-2519 y proporciona actualizaciones comerciales y resultados financieros para todo el año 2025
30/03/2026 AKTS_US — GlobeNewswire
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
30/03/2026 AKTS_US — Bitget
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
30/03/2026 AKTS_US — Stock Titan
Aktis lines up a second cancer trial after FDA clears AKY-2519
30/03/2026 AKTS_US — MarketScreener
Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
30/03/2026 AKTS_US — Yahoo Finance
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
30/03/2026 AKTS_US — Stock Titan
Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway
30/03/2026 AKTS_US — Investing.com
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial
30/03/2026 AKTS_US — Investing.com ES ← EN
La FDA autoriza el ensayo de fase 1b del AKY-2519 de Aktis Oncology Por Investing.com
20/03/2026 AKTS_US — William Blair
Economics Weekly : Wobbles in Private Debt Market

Página 4 de 6

keyboard_arrow_up